Motif Bio plc (LSE: MTFB, NASDAQ: MTFB) is developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Total raised: $3.57M
Investors 1
| Date | Name | Website |
| - | Amphion In... | amphionplc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.03.2019 | - | $3.57M | - |
Mentions in press and media 2
| Date | Title | Description |
| 18.04.2017 | Celgene, Ionis ink China drug development pacts; Motif touts positive PhIII antibiotic data | A host of biotech startups in China have been making the trek to the US to partner on promising experimental therapies. And we have news of two new pacts this week: → Shanghai-based Antengene Corporation inked a collabor... |
| 31.10.2016 | Motif Bio seeks last-gasp financing as cash crunch hits | Motif Bio (LON:MTFB) has warned that it lacks the money to continue operations. The antibiotic player is resuming its once-thwarted attempt to list on Nasdaq and considering rescheduling what it owes its CRO Covance in an attempt to keep go... |